Quantcast

Latest Emtricitabine Stories

2008-08-07 15:00:12

MEXICO CITY, Aug. 7 /PRNewswire-FirstCall/ -- GlaxoSmithKline today announced that 96-week data from the HEAT study show that once-daily EPZICOM (abacavir + lamivudine) provides comparable efficacy to once-daily Truvada(R) (tenofovir DF + emtricitabine) as a first-line option for the treatment of HIV. The data were presented today at the 17th International AIDS Conference in Mexico City, Mexico. HEAT is the first large, prospective, long-term, head-to-head trial to evaluate the safety...

2008-08-07 15:00:12

MEXICO CITY and SAN DIEGO, Aug. 7 /PRNewswire-FirstCall/ -- Ardea Biosciences, Inc. today announced that data was presented from its completed Phase 2a proof-of-concept monotherapy study of RDEA806, the Company's novel investigational non-nucleoside reverse transcriptase inhibitor (NNRTI) for patients with human immunodeficiency virus (HIV), demonstrating robust antiviral activity with a well-tolerated profile. An oral presentation of the data was given today by Dr. Graeme Moyle, Director...

2008-08-06 00:00:08

Please replace the release with the following corrected version due to multiple revisions. The corrected version reads: CASTLE DATA SHOWED BOOSTED REYATAZ(R) (ATAZANAVIR SULFATE) AND LOPINAVIR/R ACHIEVED SIMILAR RESULTS FOR UNDETECTABLE VIRAL LOAD IN TREATMENT-NAIVE HIV-1 INFECTED PATIENTS, REGARDLESS OF GENDER CASTLE gender subanalysis provides largest scale information to date about boosted protease inhibitor-based combination HIV therapy in treatment-naive women...

2008-08-05 15:01:02

MEXICO CITY, Aug. 5 /PRNewswire-FirstCall/ -- Initial treatment regimens containing once-daily or twice-daily dosing of Abbott's protease inhibitor Kaletra(R) (lopinavir/ritonavir) tablet provided similar results for controlling the virus (reducing the amount of HIV-1) and improving the immune system (increasing CD4 cells) in women compared to men and in non-whites compared to whites, according to 48-week data presented by Abbott today at the XVII International AIDS Conference (AIDS 2008)....

2008-08-05 12:01:07

MEXICO CITY, Aug. 5 /PRNewswire/ -- New phase IIb data from Tibotec Pharmaceuticals Ltd. provides additional information on the safety and efficacy of TMC278, the company's once-daily, investigational non-nucleoside reverse transcriptase inhibitor (NNRTI), as part of HIV combination therapy in treatment-naive adults. These findings were presented today at the International AIDS Conference (AIDS 2008) in Mexico City. Seventy-six percent of patients receiving the 25 mg dose of TMC278, which...

2008-07-22 18:00:55

Gilead Sciences, Inc. (Nasdaq:GILD) today announced that it has begun enrolling patients in a Phase III clinical trial of its investigational antiretroviral agent elvitegravir (GS 9137), a novel oral integrase inhibitor that is being evaluated for the treatment of HIV-1 infection. The study is designed to assess the non-inferiority of ritonavir-boosted elvitegravir, dosed once daily, compared to raltegravir (Isentress(R)), another integrase inhibitor that is dosed twice daily. The study will...

2008-07-17 09:01:20

YARDLEY, Pa., July 17 /PRNewswire/ -- Tibotec Pharmaceuticals Ltd. announced today that two major phase III efficacy trials examining TMC278, its investigational non-nucleoside reverse transcriptase inhibitor (NNRTI), in treatment-naive adults with HIV-1, are now recruiting patients. The global trials will compare the efficacy, safety and tolerability of TMC278 (25 mg) once daily oral tablet versus efavirenz (EFV), each coadministered with a background regimen of two nucleoside/nucleotide...

2008-07-10 03:00:31

MELBOURNE, Australia, July 10 /PRNewswire/ -- Cytopia announced today the appointment of Dr. Devron Averett as Chief Scientific Advisor to the company. Based in California, USA, Dr. Averett will work closely with the company's executive management team, on a part-time basis during this year, to provide scientific leadership and guidance. He has held global leadership roles at Glaxo Wellcome and Burroughs Wellcome and in recent years, at Valeant Pharmaceuticals International and Anadys...

2008-07-08 12:01:16

The French National Agency for Research on AIDS and Viral Hepatitis, with the support of Pharmasset and Gilead Sciences, has initiated the first head-to-head study of clevudine and Viread administered separately, versus their combination, for the treatment of chronic hepatitis B virus infection in non-cirrhotic patients. The study treatments include clevudine 30mg/day, tenofovir 300mg/day or the combination of both drugs administered to 150 treatment-naive hepatitis B e-antigen negative...

2008-07-02 09:01:03

CytoDyn, Inc. (Pink Sheets: CYDY) has begun GMP manufacturing and humanization of Cytolin(C), a monoclonal antibody that uses the human immune system to control HIV infection. The murine version of this product, for which there is already considerable human experience, will be used for a fast, randomized, double-blind, placebo-controlled clinical trial to supplement the data from a previous Phase Ib/IIa study. Ordinarily, pristine proof-of-principle requires a Phase III study. However, in the...


Word of the Day
omadhaun
  • A fool; a simpleton: a term of abuse common in Ireland and to a less extent in the Gaelic-speaking parts of Scotland.
This word is partly Irish in origin.